Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Referral and Consultation | 5 | 2023 | 3616 | 0.900 |
Why?
|
Oncology Service, Hospital | 2 | 2017 | 55 | 0.670 |
Why?
|
Carcinoma, Lobular | 2 | 2020 | 470 | 0.590 |
Why?
|
Abdominal Neoplasms | 1 | 2019 | 285 | 0.560 |
Why?
|
Breast Neoplasms | 18 | 2023 | 21062 | 0.510 |
Why?
|
Physician Assistants | 1 | 2018 | 190 | 0.510 |
Why?
|
Mammography | 12 | 2018 | 2423 | 0.490 |
Why?
|
Radiology | 4 | 2023 | 2089 | 0.440 |
Why?
|
Neoplasms, Second Primary | 2 | 2019 | 1056 | 0.420 |
Why?
|
Fibrocystic Breast Disease | 5 | 2000 | 101 | 0.410 |
Why?
|
Tomography, X-Ray Computed | 13 | 2023 | 20676 | 0.400 |
Why?
|
Biopsy, Needle | 8 | 2000 | 1617 | 0.360 |
Why?
|
Academic Medical Centers | 5 | 2023 | 2780 | 0.350 |
Why?
|
Lymphoma, Large B-Cell, Diffuse | 2 | 2017 | 1435 | 0.310 |
Why?
|
Breast | 8 | 2000 | 1947 | 0.300 |
Why?
|
Radiology Information Systems | 3 | 2021 | 531 | 0.290 |
Why?
|
Cancer Care Facilities | 2 | 2018 | 427 | 0.290 |
Why?
|
Inflammatory Breast Neoplasms | 2 | 2020 | 150 | 0.280 |
Why?
|
Lymphoma, T-Cell | 1 | 2009 | 308 | 0.270 |
Why?
|
Medical Oncology | 1 | 2018 | 2340 | 0.260 |
Why?
|
Liver Neoplasms | 2 | 2020 | 4350 | 0.260 |
Why?
|
Neoplasm Metastasis | 3 | 2016 | 4884 | 0.250 |
Why?
|
Evidence-Based Medicine | 1 | 2017 | 3687 | 0.240 |
Why?
|
Radiology Department, Hospital | 2 | 2019 | 407 | 0.220 |
Why?
|
Ultrasonography, Mammary | 5 | 2018 | 241 | 0.210 |
Why?
|
Magnetic Resonance Imaging | 7 | 2021 | 36543 | 0.200 |
Why?
|
Genes, erbB-2 | 2 | 2014 | 160 | 0.200 |
Why?
|
Carcinoma, Ductal, Breast | 5 | 2020 | 1084 | 0.190 |
Why?
|
Stereotaxic Techniques | 5 | 2000 | 551 | 0.190 |
Why?
|
Fluorodeoxyglucose F18 | 2 | 2020 | 2025 | 0.180 |
Why?
|
Forms and Records Control | 1 | 2020 | 158 | 0.160 |
Why?
|
Incidental Findings | 2 | 2020 | 696 | 0.150 |
Why?
|
Calcinosis | 5 | 2000 | 1478 | 0.150 |
Why?
|
Multiple Pulmonary Nodules | 1 | 2020 | 170 | 0.150 |
Why?
|
Calcium Phosphates | 1 | 2018 | 171 | 0.140 |
Why?
|
Surgical Instruments | 1 | 1999 | 379 | 0.140 |
Why?
|
Solitary Pulmonary Nodule | 1 | 2020 | 276 | 0.140 |
Why?
|
Workload | 1 | 2002 | 850 | 0.130 |
Why?
|
Environment | 1 | 2002 | 1115 | 0.130 |
Why?
|
Retrospective Studies | 18 | 2023 | 81522 | 0.130 |
Why?
|
Tumor Burden | 2 | 2014 | 1889 | 0.130 |
Why?
|
Lung Neoplasms | 6 | 2020 | 13455 | 0.130 |
Why?
|
Neoplasms | 5 | 2017 | 22350 | 0.130 |
Why?
|
Quality Improvement | 3 | 2020 | 3854 | 0.120 |
Why?
|
Foreign Bodies | 1 | 1999 | 402 | 0.120 |
Why?
|
Immunoconjugates | 1 | 2023 | 979 | 0.120 |
Why?
|
Seat Belts | 1 | 1995 | 60 | 0.120 |
Why?
|
Humans | 50 | 2023 | 766011 | 0.120 |
Why?
|
Patient Care Planning | 1 | 2020 | 906 | 0.120 |
Why?
|
Positron-Emission Tomography | 4 | 2017 | 6545 | 0.110 |
Why?
|
Neoplasm Recurrence, Local | 4 | 2017 | 9371 | 0.110 |
Why?
|
Receptors, Progesterone | 2 | 2020 | 1152 | 0.110 |
Why?
|
Female | 37 | 2023 | 396159 | 0.100 |
Why?
|
Terminology as Topic | 1 | 2020 | 1536 | 0.100 |
Why?
|
Clinical Protocols | 1 | 2018 | 1441 | 0.100 |
Why?
|
Radiopharmaceuticals | 2 | 2020 | 2699 | 0.100 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 1 | 1999 | 920 | 0.100 |
Why?
|
Receptor, erbB-2 | 3 | 2023 | 2592 | 0.090 |
Why?
|
Genes, BRCA1 | 1 | 2014 | 753 | 0.090 |
Why?
|
Receptors, Estrogen | 2 | 2020 | 2241 | 0.090 |
Why?
|
Interprofessional Relations | 1 | 2017 | 999 | 0.090 |
Why?
|
Mucous Membrane | 1 | 2013 | 656 | 0.090 |
Why?
|
Quinazolines | 2 | 2014 | 1365 | 0.090 |
Why?
|
Breast Diseases | 3 | 1998 | 436 | 0.090 |
Why?
|
Pleural Neoplasms | 1 | 2014 | 583 | 0.080 |
Why?
|
Immunoblastic Lymphadenopathy | 1 | 2009 | 40 | 0.080 |
Why?
|
Prognosis | 4 | 2019 | 29915 | 0.080 |
Why?
|
Survival Analysis | 2 | 2019 | 10086 | 0.080 |
Why?
|
Accidents, Traffic | 1 | 1995 | 818 | 0.080 |
Why?
|
Contrast Media | 3 | 2018 | 5330 | 0.080 |
Why?
|
Leukemia-Lymphoma, Adult T-Cell | 1 | 2009 | 166 | 0.080 |
Why?
|
Neoplasm Staging | 7 | 2020 | 11208 | 0.070 |
Why?
|
Middle Aged | 25 | 2020 | 223058 | 0.070 |
Why?
|
Pulmonary Embolism | 2 | 2012 | 2600 | 0.070 |
Why?
|
Delivery of Health Care, Integrated | 1 | 2016 | 954 | 0.070 |
Why?
|
Lymphoma, Large-Cell, Anaplastic | 1 | 2009 | 168 | 0.070 |
Why?
|
Aged | 21 | 2020 | 171233 | 0.070 |
Why?
|
Follow-Up Studies | 6 | 2020 | 39226 | 0.070 |
Why?
|
Nose Neoplasms | 1 | 2009 | 249 | 0.070 |
Why?
|
Decision Support Techniques | 1 | 2017 | 2003 | 0.070 |
Why?
|
Hodgkin Disease | 1 | 2014 | 1383 | 0.070 |
Why?
|
Cone-Beam Computed Tomography | 1 | 2010 | 445 | 0.070 |
Why?
|
Patient-Centered Care | 1 | 2017 | 1458 | 0.070 |
Why?
|
Central Nervous System Neoplasms | 1 | 2014 | 918 | 0.060 |
Why?
|
Adult | 21 | 2020 | 223109 | 0.060 |
Why?
|
Molecular Targeted Therapy | 1 | 2017 | 2823 | 0.060 |
Why?
|
Melanoma | 2 | 2014 | 5696 | 0.060 |
Why?
|
Diabetes Mellitus, Type 1 | 1 | 1999 | 3444 | 0.060 |
Why?
|
Uterine Cervical Neoplasms | 1 | 2016 | 2041 | 0.060 |
Why?
|
Carcinoma, Non-Small-Cell Lung | 2 | 2014 | 5388 | 0.050 |
Why?
|
Carcinoma in Situ | 2 | 2000 | 777 | 0.050 |
Why?
|
Aged, 80 and over | 9 | 2019 | 59526 | 0.050 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 2 | 2014 | 11862 | 0.050 |
Why?
|
Radiation Injuries | 1 | 2010 | 1181 | 0.050 |
Why?
|
Boston | 3 | 2019 | 9341 | 0.050 |
Why?
|
Brachytherapy | 1 | 2010 | 1221 | 0.050 |
Why?
|
Physicians | 1 | 2020 | 4587 | 0.050 |
Why?
|
Mass Screening | 1 | 2018 | 5448 | 0.050 |
Why?
|
Bone Neoplasms | 1 | 2014 | 2564 | 0.050 |
Why?
|
Radiography | 2 | 2023 | 6938 | 0.050 |
Why?
|
Iohexol | 2 | 2014 | 205 | 0.050 |
Why?
|
Brain Neoplasms | 1 | 2023 | 9071 | 0.050 |
Why?
|
Diagnosis, Differential | 3 | 2020 | 12969 | 0.050 |
Why?
|
Gastrointestinal Stromal Tumors | 1 | 2005 | 616 | 0.040 |
Why?
|
Camptothecin | 1 | 2023 | 600 | 0.040 |
Why?
|
Antineoplastic Agents | 3 | 2017 | 13639 | 0.040 |
Why?
|
Medical Record Linkage | 1 | 2019 | 286 | 0.040 |
Why?
|
Radiographic Image Enhancement | 2 | 2014 | 872 | 0.040 |
Why?
|
Workflow | 1 | 2022 | 861 | 0.040 |
Why?
|
Treatment Outcome | 7 | 2023 | 65236 | 0.040 |
Why?
|
Ultrasonography, Interventional | 2 | 2002 | 1532 | 0.030 |
Why?
|
Negotiating | 1 | 2018 | 152 | 0.030 |
Why?
|
Carcinoma, Squamous Cell | 1 | 2012 | 4046 | 0.030 |
Why?
|
Radiographic Magnification | 1 | 1996 | 18 | 0.030 |
Why?
|
Male | 11 | 2017 | 363808 | 0.030 |
Why?
|
Fibroadenoma | 1 | 1996 | 40 | 0.030 |
Why?
|
Axilla | 1 | 2018 | 615 | 0.030 |
Why?
|
Comprehensive Health Care | 1 | 2016 | 123 | 0.030 |
Why?
|
Adenocarcinoma | 1 | 2012 | 6361 | 0.030 |
Why?
|
Fat Necrosis | 1 | 1995 | 58 | 0.030 |
Why?
|
Risk | 2 | 2018 | 9600 | 0.030 |
Why?
|
Contusions | 1 | 1995 | 78 | 0.030 |
Why?
|
Piperazines | 1 | 2005 | 2546 | 0.030 |
Why?
|
Radiography, Interventional | 2 | 1999 | 1130 | 0.030 |
Why?
|
Evaluation Studies as Topic | 1 | 1996 | 1605 | 0.030 |
Why?
|
Data Collection | 1 | 2002 | 3318 | 0.030 |
Why?
|
Pyrimidines | 1 | 2005 | 3046 | 0.030 |
Why?
|
Antibodies, Neoplasm | 1 | 2014 | 282 | 0.030 |
Why?
|
Lymph Node Excision | 1 | 2018 | 1259 | 0.030 |
Why?
|
Models, Organizational | 1 | 2016 | 549 | 0.020 |
Why?
|
Cysts | 1 | 1997 | 684 | 0.020 |
Why?
|
Vinblastine | 1 | 2013 | 483 | 0.020 |
Why?
|
Kaplan-Meier Estimate | 2 | 2012 | 6508 | 0.020 |
Why?
|
Markov Chains | 1 | 2014 | 967 | 0.020 |
Why?
|
Maytansine | 1 | 2011 | 87 | 0.020 |
Why?
|
Mastectomy, Segmental | 1 | 1996 | 964 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 1 | 1996 | 1776 | 0.020 |
Why?
|
Biopsy | 2 | 1999 | 6766 | 0.020 |
Why?
|
Mastectomy | 1 | 2018 | 1847 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2018 | 3538 | 0.020 |
Why?
|
Ultrasonography | 2 | 2000 | 5997 | 0.020 |
Why?
|
Skin Neoplasms | 1 | 2009 | 5838 | 0.020 |
Why?
|
Estrogen Replacement Therapy | 1 | 1996 | 1206 | 0.020 |
Why?
|
Vacuum | 2 | 2000 | 64 | 0.020 |
Why?
|
Lymphocytes, Tumor-Infiltrating | 1 | 2014 | 1104 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1249 | 0.020 |
Why?
|
Risk Factors | 1 | 2014 | 74870 | 0.020 |
Why?
|
Neoadjuvant Therapy | 1 | 2018 | 2894 | 0.020 |
Why?
|
Statistics, Nonparametric | 1 | 2012 | 2846 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 54818 | 0.020 |
Why?
|
Angiogenesis Inhibitors | 1 | 2017 | 2046 | 0.020 |
Why?
|
Drug Administration Schedule | 1 | 2014 | 4850 | 0.020 |
Why?
|
Lymphatic Metastasis | 1 | 2013 | 2883 | 0.020 |
Why?
|
Radiation Dosage | 1 | 2014 | 1944 | 0.020 |
Why?
|
Massachusetts | 1 | 2018 | 8878 | 0.020 |
Why?
|
Cohort Studies | 2 | 2023 | 41652 | 0.020 |
Why?
|
Decision Making | 1 | 2018 | 3965 | 0.010 |
Why?
|
Observer Variation | 1 | 2010 | 2611 | 0.010 |
Why?
|
Neovascularization, Pathologic | 1 | 2014 | 2630 | 0.010 |
Why?
|
Survivors | 1 | 2014 | 2374 | 0.010 |
Why?
|
Time Factors | 2 | 1996 | 40117 | 0.010 |
Why?
|
Outpatients | 1 | 2011 | 1593 | 0.010 |
Why?
|
Lymph Nodes | 1 | 1993 | 3449 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2014 | 10731 | 0.010 |
Why?
|
Diagnostic Imaging | 1 | 2016 | 3527 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2002 | 26283 | 0.010 |
Why?
|
Cost-Benefit Analysis | 1 | 2014 | 5528 | 0.010 |
Why?
|
Sex Factors | 1 | 2014 | 10605 | 0.010 |
Why?
|
Biomedical Research | 1 | 2016 | 3457 | 0.010 |
Why?
|
Recurrence | 1 | 2012 | 8505 | 0.010 |
Why?
|
Early Detection of Cancer | 1 | 2014 | 3237 | 0.010 |
Why?
|
Benzamides | 1 | 2005 | 1376 | 0.010 |
Why?
|
Venous Thromboembolism | 1 | 2012 | 1882 | 0.010 |
Why?
|
Multivariate Analysis | 1 | 2012 | 12060 | 0.010 |
Why?
|
Automation | 1 | 2000 | 585 | 0.010 |
Why?
|
Protein Kinase Inhibitors | 1 | 2014 | 5693 | 0.010 |
Why?
|
Age Factors | 1 | 2014 | 18384 | 0.010 |
Why?
|
Smoking | 1 | 2014 | 9082 | 0.010 |
Why?
|
Hyperplasia | 1 | 2000 | 1146 | 0.010 |
Why?
|
Image Processing, Computer-Assisted | 1 | 2014 | 8927 | 0.010 |
Why?
|
Imaging, Three-Dimensional | 1 | 2010 | 4036 | 0.010 |
Why?
|
Antibodies, Monoclonal | 1 | 2014 | 9244 | 0.010 |
Why?
|
Anticoagulants | 1 | 2012 | 4863 | 0.010 |
Why?
|
Reproducibility of Results | 1 | 2014 | 20125 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2000 | 3436 | 0.010 |
Why?
|
Equipment Design | 1 | 2000 | 3487 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 21507 | 0.010 |
Why?
|
Neoplasm Invasiveness | 1 | 2000 | 3599 | 0.010 |
Why?
|
Lung | 1 | 2010 | 10031 | 0.010 |
Why?
|
Young Adult | 1 | 2011 | 59870 | 0.000 |
Why?
|
Case-Control Studies | 1 | 1997 | 22230 | 0.000 |
Why?
|
Adolescent | 1 | 2005 | 88804 | 0.000 |
Why?
|